Stay updated with breaking news from Based Regimens. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced it would focus its development efforts on advancing avexitide in
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; ext...
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
First presentation of RSV Older Adult vaccine candidate's pivotal phase III efficacy and safety data New data showing Shingrix... | October 12, 2022